Neo-ALTTO trial expected to begin recruiting in September 2007
The Neo-ALTTO trial is a companion trial to ALTTO that will evaluate the effectiveness of lapatinib (Tykerb®/Tyverb®) as neoadjuvant therapy for HER2 (ErbB2)-positive breast cancer.
The Neo-ALTTO trial will explore whether treatment with lapatinib, trastuzumab (Herceptin®), or their combination, together with a traditional chemotherapy (paclitaxel), can reduce the size of breast tumours prior to surgery.
This global trial will recruit 450 women with HER2 (ErbB2)-positive breast cancer at about 130 sites (hospitals or doctor’s offices) in approximately 30 countries. Patients will receive study treatments for a total of 1 year (18 weeks presurgery, and 34 weeks postsurgery). The trial is expected to open in September 2007.
Neo-ALTTO is organised by BIG (Breast International Group) and the Spanish-based SOLTI (SOLid Tumour Intensification) Group. GlaxoSmithKline is also collaborating in the trial.
For information about ALTTO, a companion trial evaluating lapatinib in women who have had surgery to remove a breast cancer tumour, click on the ALTTO button at left.
Tykerb and Tyverb are registered trade marks of the GlaxoSmithKline group of companies.
Herceptin is a registered trade mark of Genentech, Inc.
The Neo-ALTTO trial will explore whether treatment with lapatinib, trastuzumab (Herceptin®), or their combination, together with a traditional chemotherapy (paclitaxel), can reduce the size of breast tumours prior to surgery.
This global trial will recruit 450 women with HER2 (ErbB2)-positive breast cancer at about 130 sites (hospitals or doctor’s offices) in approximately 30 countries. Patients will receive study treatments for a total of 1 year (18 weeks presurgery, and 34 weeks postsurgery). The trial is expected to open in September 2007.
Neo-ALTTO is organised by BIG (Breast International Group) and the Spanish-based SOLTI (SOLid Tumour Intensification) Group. GlaxoSmithKline is also collaborating in the trial.
For information about ALTTO, a companion trial evaluating lapatinib in women who have had surgery to remove a breast cancer tumour, click on the ALTTO button at left.
Tykerb and Tyverb are registered trade marks of the GlaxoSmithKline group of companies.
Herceptin is a registered trade mark of Genentech, Inc.
